Potential impact of nirsevimab and bivalent maternal vaccine against RSV bronchiolitis in infants: A population-based modelling study
Background: A new monoclonal antibody (nirsevimab; Beyfortus®) and a bivalent prefusion RSV vaccine (Abrysvo®) for maternal immunization have been approved recently. This is a modelling study to estimate the potential impact of different immunization programs with these products on RSV-bronchiolitis...
-д хадгалсан:
Үндсэн зохиолчид: | , , , , , |
---|---|
Формат: | Ном |
Хэвлэсэн: |
Elsevier,
2024-08-01T00:00:00Z.
|
Нөхцлүүд: | |
Онлайн хандалт: | Connect to this object online. |
Шошгууд: |
Шошго нэмэх
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|
Интернэт
Connect to this object online.3rd Floor Main Library
Зохиогчийн тэмдэгт: |
A1234.567 |
---|---|
Хуулбар 1 | Бэлэн |